Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. has received approval for its initial public offering (IPO) of A-shares and will be listed on the main board, with the issuance price set at 26.50 yuan per share and a total of 41,139,407 shares to be issued [1][2]. Issuance Details - The IPO will consist of a combination of strategic placement, offline issuance, and online issuance, with the initial strategic placement amounting to 4,113,940 shares, representing 10% of the total issuance [1][2]. - The final strategic placement quantity was adjusted to 1,772,075 shares, approximately 4.31% of the total issuance, with the difference being allocated to offline issuance [2][3]. Subscription and Allocation - The offline issuance quantity after the strategic placement adjustment is 28,259,832 shares, accounting for 71.78% of the remaining shares, while the online issuance quantity is 11,107,500 shares, representing 28.22% [2][3]. - The initial effective subscription multiple for the online issuance was approximately 7,518.35 times, leading to the activation of the allocation mechanism, redistributing 15,747,000 shares from offline to online issuance [3]. Financial Statistics - The total amount raised from the online investors was approximately 707.77 million yuan, with 26,708,402 shares subscribed [8]. - The offline investors subscribed for 12,512,137 shares, totaling approximately 331.57 million yuan [8]. Underwriting and Fees - The total issuance costs are approximately 112.30 million yuan, including underwriting and advisory fees of 74.18 million yuan, audit and verification fees of 17.88 million yuan, and legal fees of 8.49 million yuan [10][11].
山东威高血液净化制品股份有限公司 首次公开发行股票并在主板上市发行结果公告